

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of the claims in this application:

#### Listing of the Claims:

Claims 1–117. (Canceled).

118. (Currently Amended) A method of diagnosing a cancer disease ~~characterized by expression or abnormal expression of a tumor-associated antigen~~ comprising detection of ~~the~~ a tumor-associated antigen ~~or a portion thereof~~ in a biological sample isolated from a patient, wherein the tumor-associated antigen is selected from the group consisting of:

- (i) a polypeptide of SEQ ID NO: 22 ~~or a portion thereof; and~~
- (ii) a polypeptide encoded by a nucleic acid of SEQ ID NO: 19 ~~or a portion thereof; and~~
- (iii) ~~a polypeptide encoded by a nucleic acid that is complementary to a nucleic acid of SEQ ID NO: 19 or a portion thereof;~~

wherein detection of the tumor-associated antigen in the biological sample in an amount greater than an amount of the tumor-associated antigen in a normal biological sample indicates ~~the disease~~ cancer.

119. (Currently Amended) The method as claimed in claim 118, in which the detection comprises:

- (i) contacting the biological sample with an agent which binds specifically to the tumor-associated antigen ~~or the portion thereof;~~ and
- (ii) detecting a complex formed between the agent and the tumor-associated antigen ~~or the portion thereof~~.

120. (Previously Presented) The method as claimed in claim 119, wherein the agent is an antibody.

121. (Previously Presented) The method as claimed in claim 119, wherein the agent is labeled with a detectable marker.

122. (Previously Presented) The method as claimed in claim 121, wherein the detectable marker is a radioactive marker or an enzymatic marker.

123. (Previously Presented) The method as claimed in claim 118, wherein the biological sample comprises body fluid or body tissue.

124. (Currently Amended) The method as claimed in 118, in which the ~~disease~~ cancer is characterized by expression or abnormal expression of two or more different tumor-associated antigens and in which detection comprises detection of two or more different tumor-associated antigens ~~or portions thereof~~.

Claims 125-134. (Canceled)